Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Aug 29

PMID 39199550

Authors

Muntajin Rahman

Khadija Akter

Kazi Rejvee Ahmed

Md Maharub Hossain Fahim

Nahida Aktary

Moon Nyeo Park

Sang-Won Shin

Bonglee Kim

Affiliations

Soon will be listed here.

Abstract

Castration-resistant prostate cancer (CRPC) remains a significant therapeutic challenge due to its resistance to standard androgen deprivation therapy (ADT). The emergence of androgen receptor splice variant 7 (AR-V7) has been implicated in CRPC progression, contributing to treatment resistance. Current treatments, including first-generation chemotherapy, androgen receptor blockers, radiation therapy, immune therapy, and PARP inhibitors, often come with substantial side effects and limited efficacy. Natural compounds, particularly those derived from herbal medicine, have garnered increasing interest as adjunctive therapeutic agents against CRPC. This review explores the role of AR-V7 in CRPC and highlights the promising benefits of natural compounds as complementary treatments to conventional drugs in reducing CRPC and overcoming therapeutic resistance. We delve into the mechanisms of action underlying the anti-CRPC effects of natural compounds, showcasing their potential to enhance therapeutic outcomes while mitigating the side effects associated with conventional therapies. The exploration of natural compounds offers promising avenues for developing novel treatment strategies that enhance therapeutic outcomes and reduce the adverse effects of conventional CRPC therapies. These compounds provide a safer, more effective approach to managing CRPC, representing a significant advancement in improving patient care.

References

Hur J, Kim D . Berberine inhibited radioresistant effects and enhanced anti-tumor effects in the irradiated-human prostate cancer cells. Toxicol Res. 2013; 26(2):109-15. PMC: 3834470. DOI: 10.5487/TR.2010.26.2.109. View

Khan T, Bhar K, Samanta R, Bhatt S, Singh M, Rani R . A bis-quinoline ruthenium(II) arene complex with submicromolar cytotoxicity in castration-resistant prostate cancer cells. Chem Commun (Camb). 2024; 60(12):1579-1582. DOI: 10.1039/d3cc05083a. View

Khurana N, Talwar S, Chandra P, Sharma P, Abdel-Mageed A, Mondal D . Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells. Int J Oncol. 2016; 49(4):1609-19. DOI: 10.3892/ijo.2016.3641. View

Mbese Z, Khwaza V, Aderibigbe B . Curcumin and Its Derivatives as Potential Therapeutic Agents in Prostate, Colon and Breast Cancers. Molecules. 2019; 24(23). PMC: 6930580. DOI: 10.3390/molecules24234386. View

GuhaThakurta D, Sheikh N, Fan L, Kandadi H, Meagher T, Hall S . Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res. 2015; 21(16):3619-30. PMC: 4868054. DOI: 10.1158/1078-0432.CCR-14-2334. View

Baldwin E, Osheroff N . Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents. 2005; 5(4):363-72. DOI: 10.2174/1568011054222364. View

Kciuk M, Alam M, Ali N, Rashid S, Glowacka P, Sundaraj R . Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications. Molecules. 2023; 28(13). PMC: 10343677. DOI: 10.3390/molecules28135246. View

Hahm E, Arlotti J, Marynowski S, Singh S . Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin Cancer Res. 2008; 14(4):1248-57. DOI: 10.1158/1078-0432.CCR-07-1926. View

Li C, Sun H, Wei W, Liu Q, Wang Y, Zhang Y . Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. Cell Oncol (Dordr). 2020; 43(6):1099-1116. DOI: 10.1007/s13402-020-00544-2. View

10.

Mukund V, Mukund D, Sharma V, Mannarapu M, Alam A . Genistein: Its role in metabolic diseases and cancer. Crit Rev Oncol Hematol. 2017; 119:13-22. DOI: 10.1016/j.critrevonc.2017.09.004. View

11.

Gim H, Park J, Jung M, Houk K . Conformational dynamics of androgen receptors bound to agonists and antagonists. Sci Rep. 2021; 11(1):15887. PMC: 8342701. DOI: 10.1038/s41598-021-94707-2. View

12.

Moilanen A, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G . Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015; 5:12007. PMC: 4490394. DOI: 10.1038/srep12007. View

13.

Cheon C, Ko S . Synergistic effects of natural products in combination with anticancer agents in prostate cancer: A scoping review. Front Pharmacol. 2022; 13:963317. PMC: 9510769. DOI: 10.3389/fphar.2022.963317. View

14.

Shigemura K, Arbiser J, Sun S, Zayzafoon M, Johnstone P, Fujisawa M . Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer. 2007; 109(7):1279-89. DOI: 10.1002/cncr.22551. View

15.

Herrmann D, Schreiber A, Ciotkowska A, Strittmatter F, Waidelich R, Stief C . Honokiol, a constituent of Magnolia species, inhibits adrenergic contraction of human prostate strips and induces stromal cell death. Prostate Int. 2014; 2(3):140-6. PMC: 4186958. DOI: 10.12954/PI.14055. View

16.

Figueiredo A, Costa L, Mauricio M, Figueira L, Ramos R, Martins-da-Silva C . Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends. Clin Drug Investig. 2022; 42(8):631-642. PMC: 9338100. DOI: 10.1007/s40261-022-01178-y. View

17.

Zhu M, Horbinski C, Garzotto M, Qian D, Beer T, Kyprianou N . Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70(20):7992-8002. PMC: 2978028. DOI: 10.1158/0008-5472.CAN-10-0585. View

18.

Higano C, Schellhammer P, Small E, Burch P, Nemunaitis J, Yuh L . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16):3670-9. DOI: 10.1002/cncr.24429. View

19.

Nilsson S, Cislo P, Sartor O, Vogelzang N, Coleman R, OSullivan J . Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016; 27(5):868-74. PMC: 4843190. DOI: 10.1093/annonc/mdw065. View

20.

Halabi S, Armstrong A, Sartor O, de Bono J, Kaplan E, Lin C . Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013; 31(31):3944-50. PMC: 3805930. DOI: 10.1200/JCO.2013.50.3201. View